Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 261

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study

Wang, Qiuhe, Xia, Dongdong, Bai, Wei, Wang, Enxin, Sun, Junhui, Huang, Ming, Mu, Wei, Yin, Guowen, Li, Hailiang, Zhao, Hui, Li, Jing, Zhang, Chunqing, Zhu, Xiaoli, Wu, Jianbing, Li, Jiaping, Gong, Weidong, Li, Zixiang, Lin, Zhengyu, Pan, Xingnan, Shi, Haibin, Shao, Guoliang, Liu, Jueshi, Yang, Shufa, Zheng, Yanbo, Xu, Jian, Song, Jinlong, Wang, Wenhui, Wang, Zhexuan, Zhang, Yuelin, Ding, Rong, Zhang, Hui, Yu, Hui, Zheng, Lin, Gu, Weiwei, You, Nan, Wang, Guangchuan, Zhang, Shuai, Feng, Long, Liu, Lin, Zhang, Peng, Li, Xueda, Chen, Jian, Xu, Tao, Zhou, Weizhong, Zeng, Hui, Zhang, Yongjin, Huang, Wukui, Jiang, Wenjin, Zhang, Wen, Shao, Wenbo, Li, Lei, Niu, Jing, Yuan, Jie, Li, Xiaomei, Lv, Yong, Li, Kai, Yin, Zhanxin, Xia, Jielai, Fan, Daiming, Han, Guohong·2019·Journal of Hepatology

Abstract

BACKGROUND & AIMS Previous prognostic scores for transarterial chemoembolization (TACE) were mainly derived from real-world settings, which are beyond guideline recommendations. A robust model for outcome prediction and risk stratification of recommended TACE candidates is lacking. We aimed to develop an easy-to-use tool specifically for these patients. METHODS Between January 2010 and May 2016, 1,604 treatment-naïve patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh A5-B7 and performance status 0 undergoing TACE were included from 24 tertiary centres. Patients were randomly divided into training (n = 807) and validation (n = 797) cohorts. A prognostic model was developed and subsequently validated. Predictive performance and discrimination were further evaluated and compared with other prognostic models. RESULTS The final presentation of the model was "linear predictor = largest tumour diameter (cm) + tumour number", which consistently outperformed other currently available models in both training and validation datasets as well as in different subgroups. The thirtieth percentile and the third quartile of the linear predictor, namely 6 and 12, were further selected as cut-off values, leading to the "six-and-twelve" score which could divide patients into 3 strata with the sum of tumour size and number ≤6, >6 but ≤12, and >12 presenting significantly different median survival of 49.1 (95% CI 43.7-59.4) months, 32.0 (95% CI 29.9-37.5) months, and 15.8 (95% CI 14.1-17.7) months, respectively. CONCLUSIONS The six-and-twelve score may prove an easy-to-use tool to stratify recommended TACE candidates (Barcelona Clinic Liver Cancer stage-A/B) and predict individual survival with favourable performance and discrimination. Moreover, the score could stratify these patients in clinical practice as well as help design clinical trials with comparable criteria involving these patients. Further external validation of the score is required. LAY SUMMARY There is currently no prognostic model specifically developed for recommended or ideal transarterial chemoembolization (TACE) candidates with hepatocellular carcinoma, despite these patients being frequently identified as the best target population in pivotal randomized controlled trials. The six-and-twelve score provides patient survival prediction, especially in ideal candidates of TACE, outperforming other currently available models in both training and validation sets, as well as different subgroups. With cut-off values of 6 and 12, the score can stratify ideal TACE candidates into 3 strata with significantly different outcomes and may shed light on risk stratification of these patients in clinical practice as well as in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2019.01.013

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 261

Metadata

Authors
Wang, Q., Xia, D., Bai, W., Wang, E., Sun, J., Huang, M., Mu, W., Yin, G., Li, H., Zhao, H., Li, J., Zhang, C., Zhu, X., Wu, J., Li, J., Gong, W., Li, Z., Lin, Z., Pan, X., Shi, H., Shao, G., Liu, J., Yang, S., Zheng, Y., Xu, J., Song, J., Wang, W., Wang, Z., Zhang, Y., Ding, R., Zhang, H., Yu, H., Zheng, L., Gu, W., You, N., Wang, G., Zhang, S., Feng, L., Liu, L., Zhang, P., Li, X., Chen, J., Xu, T., Zhou, W., Zeng, H., Zhang, Y., Huang, W., Jiang, W., Zhang, W., Shao, W., Li, L., Niu, J., Yuan, J., Li, X., Lv, Y., Li, K., Yin, Z., Xia, J., Fan, D., & Han, G.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2019-05
Volume
70
Issue
5
Pages
893-903
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2909659250
Cited by
261
References
60
FWCI
15.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. https://app.cochat.ai/papers/10.1016/j.jhep.2019.01.013
The paper
Wang, Q., Xia, D., Bai, W., Wang, E., Sun, J., Huang, M., Mu, W., Yin, G., Li, H., Zhao, H., Li, J., Zhang, C., Zhu, X., Wu, J., Li, J., Gong, W., Li, Z., Lin, Z., Pan, X., . . . Han, G. (2019). Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2019.01.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.